GSK3B and hereditary sensory and autonomic neuropathy: As GSK3β was shown to inhibit the degradation process of β-catenin, we found corresponding results that phosphorylated GSK3β leads to an increase of cellular β-catenin in CIP treated DPCs (Figure 4(a)).